TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT (NCT04967495) | Clinical Trial Compass
UnknownNot Applicable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
China171 participantsStarted 2021-07-09
Plain-language summary
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len) for hepatocellular carcinoma (HCC) with portal vein branch tumor thrombus (branch PVTT).
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between18 and 75 years.
✓. HCC confirmed by histopathology and/or cytology, or diagnosed clinically.
✓. Accompanied with tumor thrombus involving unilateral portal vein branch.
✓. Child-Pugh class A or B.
✓. Eastern Cooperative Group performance status (ECOG) score of 0-2.
✓. Serum bilirubin ≤ 51.3 μmol/L, albumin ≥ 28g/L, ALT and AST ≤ 5 times of the upper normal limit, and creatinine ≤ 20g/L.
✓. Prothrombin time prolonged for less than 4s or international normalized ratio \< 1.7.